Unknown

Dataset Information

0

Pharmacological Analysis of GABAA Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABAA Receptors' Ligands.


ABSTRACT: Two groups of facts have been established in previous drug development studies of the non-benzodiazepine anxiolytic fabomotizole. First, fabomotizole prevents stress-induced decrease in binding ability of the GABAA receptor's benzodiazepine site. Second, fabomotizole is a Sigma1R chaperone agonist, and exposure to Sigma1R antagonists blocks its anxiolytic effect. To prove our main hypothesis of Sigma1R involvement in GABAA receptor-dependent pharmacological effects, we performed a series of experiments on BALB/c and ICR mice using Sigma1R ligands to study anxiolytic effects of benzodiazepine tranquilizers diazepam (1 mg/kg i.p.) and phenazepam (0.1 mg/kg i.p.) in the elevated plus maze test, the anticonvulsant effects of diazepam (1 mg/kg i.p.) in the pentylenetetrazole-induced seizure model, and the hypnotic effects of pentobarbital (50 mg/kg i.p.). Sigma1R antagonists BD-1047 (1, 10, and 20 mg/kg i.p.), NE-100 (1 and 3 mg/kg i.p.), and Sigma1R agonist PRE-084 (1, 5, and 20 mg/kg i.p.) were used in the experiments. Sigma1R antagonists have been found to attenuate while Sigma1R agonists can enhance GABAARs-dependent pharmacological effects.

SUBMITTER: Voronin MV 

PROVIDER: S-EPMC10253922 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacological Analysis of GABA<sub>A</sub> Receptor and Sigma1R Chaperone Interaction: Research Report I-Investigation of the Anxiolytic, Anticonvulsant and Hypnotic Effects of Allosteric GABA<sub>A</sub> Receptors' Ligands.

Voronin Mikhail V MV   Shangin Stanislav V SV   Litvinova Svetlana A SA   Abramova Elena V EV   Kurbanov Rustam D RD   Rybina Inna V IV   Vakhitova Yulia V YV   Seredenin Sergei B SB  

International journal of molecular sciences 20230531 11


Two groups of facts have been established in previous drug development studies of the non-benzodiazepine anxiolytic fabomotizole. First, fabomotizole prevents stress-induced decrease in binding ability of the GABA<sub>A</sub> receptor's benzodiazepine site. Second, fabomotizole is a Sigma1R chaperone agonist, and exposure to Sigma1R antagonists blocks its anxiolytic effect. To prove our main hypothesis of Sigma1R involvement in GABA<sub>A</sub> receptor-dependent pharmacological effects, we perf  ...[more]

Similar Datasets

| S-EPMC8196847 | biostudies-literature
| S-EPMC7413181 | biostudies-literature
| S-EPMC8225436 | biostudies-literature
| S-EPMC3519985 | biostudies-literature
| S-EPMC6295415 | biostudies-literature
| S-EPMC6154531 | biostudies-literature
| S-EPMC10153171 | biostudies-literature
| S-EPMC8477953 | biostudies-literature
| S-EPMC5368958 | biostudies-literature
| S-EPMC7317483 | biostudies-literature